The full name of the 13-valent pneumonia vaccine is 13-valent pneumococcal polysaccharide conjugate vaccine. 13-valent pneumococcal polysaccharide conjugate vaccine does not protect against Mycoplasma pneumonia. The 13-valent pneumococcal polysaccharide conjugate vaccine contains 13 serotypes of pneumococcal pod polysaccharides bound to a carrier protein, and can be used to prevent pneumococcal diseases such as acute otitis media, pneumonia, meningitis, bacteremia and sinusitis, etc. Since Mycoplasma and pneumococcus are two completely different pathogens, it has no preventive effect on Mycoplasma pneumonia. The 13-valent Pneumococcal Polysaccharide Conjugate Vaccine is indicated for children between 6 weeks of age and 5 years of age. In addition, this vaccine should not be administered to those with a history of previous allergic reactions or severe allergic reactions to any of the components of this vaccine, and individuals with fever, acute illness, and active chronic diseases (e.g., acute and chronic hepatitis, etc.) are advised to receive this vaccine only after their condition has stabilized. Adverse reactions such as fever, diarrhea, and vomiting may occur in vaccinated individuals. It is recommended that the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine be administered under the supervision of a physician, and that the physician be informed of any adverse reactions, such as fever, that occur after vaccination.